Clinical Research Department

Instituto Cardiovascular San Luis

Myocardial Infarction

Coronary Disease

Heart Diseases

Atrial Flutter

Heart Failure

Infarction

Coronary Artery Disease

Myocardial Ischemia

Atrial Fibrillation

Obesity

Evolocumab

Tirzepatide

LY3298176

Amgen

Lilly

Brazilian Clinical Research Institute

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Instituto Cardiovascular San Luis | Clinical Research Department

Site insights

Work at this site?

Active trials

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)

Trial sponsors